Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio NEW ORLEANS — Young people with type 2 ...

Patients on tirzepatide also experienced more metabolic benefits, such as greater reductions in weight and HbA1c, compared with dulaglutide.

In a large randomized trial involving patients with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide in reducing ...

Dulaglutide (Trulicity) effectively boosted blood glucose control in youth with type 2 diabetes, the AWARD-PEDS trial found. Over the 26-week trial, 51% of youth (ages 10 to <18 years) treated with ...

The diabetes drug dulaglutide may dramatically reduce a woman’s chance of gaining weight after stopping the habit of smoking. Gender differences in weight gain during attempted and successful smoking ...

Another glucagon-like peptide-1 (GLP1) agonist, dulaglutide (Trulicity, Lilly), is poised to be a new option for glycemic control in youth ages 10 to 18 with type 2 diabetes, given as a weekly ...

Bagsværd, Denmark, 16 August 2017 - Novo Nordisk today announced the SUSTAIN 7 trial results, demonstrating that people with type 2 diabetes treated with once-weekly semaglutide experienced superior ...

Adults with type 2 diabetes and mild to moderate chronic kidney disease assigned the once-weekly GLP-1 receptor agonist dulaglutide experienced a similar reduction in HbA1c vs. those assigned insulin ...

Company Shares Top-line Results on Three Completed AWARD Trials INDIANAPOLIS, Oct. 22, 2012 -- /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three ...

Results from a phase 3 study of patients with type 2 diabetes uncontrolled with metformin indicate that adding injections of the investigational glucagonlike peptide 1 (GLP-1)–receptor agonist ...

In combination with metformin, advantages and disadvantages of Dulaglutide in type 2 diabetes are balanced, reviewers have concluded. Since 2014 dulaglutide has been approved alone or in combination ...